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Abstract
A 66-year-old man with thrombocytosis was brought to our hospital to undergo removal of a left ventricular
thrombus. He had developed cerebral infarction 6 days before presenting to the hospital and suffered from right
incomplete hemiparalysis. Blood tests on admission revealed his platelet count to be 124.3 × 104/μl. The urgent
removal operation was performed under general anesthesia. For carrying out extracorporeal circulation (ECC),
approximately three times as much heparin as expected was needed, as well as antithrombin III (AT III)
administration. This met the definition of heparin resistance. The thrombus was removed and surgical left
ventricular reconstruction was performed. Aspirin and warfarin were initiated on postoperative day 5. A bone
marrow biopsy was performed on postoperative day 8, which revealed hypercellular marrow with megakaryocyte
proliferation, and the patient was diagnosed as having essential thrombocythemia (ET). Although hydroxycarbamide
administration started on postoperative day 10, his platelet count increased to 290.7 × 104/μl on postoperative day
13. The counts descended gradually, and on postoperative day 34, his platelet count reached the normal range and
he was discharged from the hospital. In the perioperative period, his new neurologic abnormality did not appear.
Addition of heparin, administration of AT III, and coating the cardiopulmonary bypass circuit with heparin or
macromolecular polymer prevented clot formation and enabled safe ECC in a patient with ET and a high platelet
count.
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Background
Essential thrombocythemia (ET) is classified as a myelopro-
liferative neoplasm. The characteristics are megakaryocyte
proliferation in the bone marrow, continuously very high
platelet counts (>45 × 104/μl), and morphological abnor-
malities of platelets. ET is ruled out if there are morpho-
logical abnormalities of the red or white blood cells.
Progression of ET causes both thrombotic and hemorrhagic
diathesis. Thrombotic events occur more often than
hemorrhagic events, and thrombi form more frequently in
arteries than in veins. Effective treatments are anticoagulant
therapy and some drugs that reduce platelet numbers, such
as hydroxyurea, anagrelide, Janus kinase 2 (JAK2) inhibi-
tors, and α-interferon [1].
There are no clear guidelines on the pre- or postopera-
tive management of patients with ET undergoing cardiac
surgery. There have been some case reports on patients
with ET who underwent cardiac surgery under cardiopul-
monary bypass (CPB). In two reports, the platelet count
was reduced to a normal range using hydroxyurea or α-
interferon before surgery was performed [2, 3]. In the
other reports, the platelet count was reduced by thera-
peutic plateletpheresis procedures preoperatively [4, 5].
One case report on urgent cardiac surgery under CPB for
a patient with ET and a high platelet count was published
in Japanese [6]. We present a case report of a patient with
ET and a high platelet count who underwent urgent left
ventricular thrombus removal under CPB.
Case presentation
A 66-year-old man weighing 49.9 kg developed cere-
bral infarction and right hemiparalysis. Transthoracic
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echocardiography (TTE) showed globally decreased left
ventricular function (visual ejection fraction 30 %) and
a left ventricular foreign body. Infectious endocarditis
was suspected because he also had a fever and elevated
C-reactive protein levels and white blood cell count.
Antibiotics were administered, but after 2 days the for-
eign body grew. His platelet count was 130.6 × 104/μl,
which suggested thrombocytosis and left ventricular
thrombus. Administration of heparin did not improve
the thrombus and 6 days after the onset of cerebral in-
farction the patient was urgently brought to our hos-
pital to have the thrombus removed.
He explained that he had undergone a procedure for a
gastric ulcer 1 year before, but he was not aware of his
cardiac abnormality on admission. He suffered from
right hemiparalysis. His platelet count was 124.3 × 104/
μl, his white blood cell count was 156 × 102/μl, and his
red blood cell count was 536 × 104/μl. Abnormal white
blood cells were not observed. TTE showed severe hypo-
kinesis and akinesis from the middle to the apical areas
of the left ventricle. The visual ejection fraction was
approximately 35 %. The left ventricular thrombus was
located in the septal segments and was 15.5 × 30.0 mm
as measured by TTE.
The urgent removal operation was performed under
general anesthesia as soon as hospitalization and several
examinations were accomplished. General anesthesia was
induced with midazolam, fentanyl, and rocuronium, and
maintained with propofol, remifentanil, fentanyl, and
rocuronium. Transesophageal echocardiography (TEE)
showed a fragile thrombus, not in the left atrial appendage
but in the left ventricle (Fig. 1). The activated coagulation
time (ACT) was 182 s, and the antithrombin III (AT III)
level was 74.6 %. After heparin sodium 360 IU per kg
bodyweight (IU/kg) was administered intravenously, the
ACT reached 261 s. Heparin sodium 400 IU/kg was added
and CPB was started. Despite administration of heparin,
the ACT only reached 350 s, which was not long enough
to carry out extracorporeal circulation (ECC). AT III con-
centrate (NeuartTM) 750 IU and heparin sodium 100 IU/
kg were administered and the ACT extended to 459 s.
The patient’s AT III level was examined after administra-
tion of the AT III concentrate and was found to be 54.9 %.
Further, AT III was administered (750 IU), and the AT III
level reached 75.3 % (Fig. 2).
The areas of the left ventricle supplied by the left
anterior descending (LAD) artery were thin and a left
ventricular aneurysm that contained the thrombus was
observed. The thrombus was very fragile and partially
liquid. The border between normal tissue and scar tissue
of the left ventricle was clear, and the size of the scar
was 60 × 40 mm. The thrombus was removed and surgi-
cal left ventricular reconstruction was performed. A CPB
circuit coated by heparin or macromolecular polymer
was used and no clots were seen in the circuit. An intra-
aortic balloon pump (IABP) was inserted and used to
keep systolic blood pressure low and prevent left ven-
tricular rupture. Protamine sulfate 90 mg (1.8 mg/kg)
was administered intravenously to neutralize the hep-
arin, and the ACT returned to 163 s. The regional cere-
bral oxygen saturation was monitored by near infrared
spectroscopy during anesthesia; no obvious changes
were observed. The anesthetic duration was 6 h 29 min,
the ECC time was 2 h 44 min, and the cross-clamp time
was 1 h 59 min. Blood loss was 1401 g. Besides crystal-
loid solution, 1200 ml of fresh frozen plasma (FFP),
Fig. 1 Left ventricular thrombus observed by transesophageal echocardiography under general anesthesia. The thrombus ( ) was mobile and
was located in the septal areas
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1400 ml of packed red blood cells, and 350 ml of albu-
min were administered.
The patient entered an intensive care unit after sur-
gery and protamine sulfate 50 mg was administered
intravenously because his ACT was still 230 s. The
post-surgical platelet count was 55.9 × 104/μl. Bacterial
cells were not found in the removed thrombus. The
IABP was removed on postoperative day 3, and the pa-
tient was taken off mechanical ventilation support on
postoperative day 6. Aspirin and warfarin were initi-
ated on postoperative day 5. A bone marrow biopsy
was performed 8 days after the surgery, which revealed
hypercellular marrow with megakaryocyte prolifera-
tion. The patient was diagnosed as having ET. Al-
though hydroxycarbamide administration started on
postoperative day 10, the patient’s platelet count in-
creased to 290.7 × 104/μl on postoperative day 13. The
count descended gradually, and on postoperative day
27 it reached 100 × 104/μl. In the perioperative period,
his new neurologic abnormality did not appear. On
postoperative day 28, cardiac angiography revealed
that segments 7 and 8 of the LAD artery had 90 %
stenosis. Left ventriculography showed akinesis of seg-
ments 3 and 6 but no thrombus. On postoperative day
34, the patient’s platelet count was 37.4 × 104/μl and
he was discharged from the hospital.
Discussion
Patients with ET frequently develop thrombotic attacks
especially in the brain, heart, and distal arteries [1].
Removal from the heart has risks, and one patient with
right atrial thrombus was reported to choose anticoagu-
lant therapy without surgical removal [7]. Our patient
developed cerebral infarction, and the size of his
thrombus did not reduce despite heparinization; there-
fore, he decided to undergo a removal operation under
CPB. His high platelet count was strongly suspected to
be caused by ET before the surgery. However, there was
not sufficient time to make a diagnosis or to reduce the
platelet count using cytoreductive drugs because the left
ventricular thrombus was mobile and the cerebral in-
farction may have worsened.
A 22-year-old patient with ET was reported to undergo
aortic valve replacement under CPB after his platelet
count was reduced to 30.1 × 104/μl by treatment with α-
interferon [2]. A 64-year-old patient with ET was also re-
ported to receive mitroaortic valve replacement under
CPB after his platelet count was reduced to 30 × 104/μl by
treatment with hydroxyurea [3]. A 54-year-old patient
with ET was reported to have cardiac artery bypass sur-
gery under CPB with a high platelet count: 99 × 104/μl [6].
This case was urgent and there was not sufficient time to
reduce the platelet count. In this case, heparin 300 IU/kg
Fig. 2 Changes in ACT and AT III. More heparin than expected was needed to carry out extracorporeal circulation. The patient’s AT III levels
decreased during surgery, and administration of AT III was needed. Less protamine than expected was needed to neutralize the heparin effect.
ACT activated coagulation time, AT III antithrombin III, CPB cardiopulmonary bypass
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was not enough to increase the ACT to longer than 400 s,
and eventually 500 IU/kg heparin was needed. The ECC
time was 1 h 10 min, and heparin 200 IU/kg was added to
keep the ACT longer than 400 s under CPB. However,
1.5 mg/kg protamine was sufficient to neutralize the hep-
arin effect. Perioperative thrombotic events did not occur
in this case.
Some abstracts reporting on CPB for patients with ET
were presented at academic conferences in Japan. An
81-year-old patient with ET was reported to undergo
aortic valve replacement under CPB with a high platelet
count of 139.8 × 104/μl [8]. Heparin 300 IU/kg was ad-
ministered before ECC and nafamostat mesilate 30 mg/h
was continuously delivered during the procedure. The
CPB circuit was not coated with heparin or other anti-
coagulant substances. Despite delivering anticoagulant
drugs, clots were observed in the reservoir and the aortic
filter, which eventually needed to be changed. Another
summary reported that a 57-year-old patient with ET
had mitral valve plasty under CPB with a platelet count
of 121.8 × 104/μl [9]. The dose of heparin administered
was not referred to, but delivering heparin continuously
into the CPB circuit and using a CPB circuit coated with
heparin enabled safe ECC and the reservoir did not need
to be changed. In another abstract, the authors reported
that a 64-year-old patient who had suspected ET under-
went mitral valve plasty under CPB with a platelet count
of 73.2 × 104/μl [10]. Heparin (200 IU/kg) was adminis-
tered before ECC and at that point, the ACT was 236 s.
The CPB circuit was coated with anticoagulants, but
these were not referred to in detail. During the 2 h
41 min ECC, 50,000 IU heparin was delivered. ACT was
checked seven times during CPB, but only twice was it
longer than 400 s. The reservoir did not need to be
changed, although clots were observed. These case re-
ports demonstrate heparin resistance and the hypercoag-
ulable state and difficulties experienced with CPB in
patients with ET.
A 73-year-old man with ET was reported to undergo
cardiac surgery after his platelet count had been re-
duced to a normal range using three therapeutic plate-
letpheresis procedures [4]. Therapeutic plateletpheresis
is a useful method for rapidly reducing the platelet
count, but there are no clear guidelines for this proced-
ure for ET patients. The presence of nonfunctional
platelets in ET patients poses a problem in establishing
a safe preoperative baseline platelet count. Furthermore, it
is controversial whether this reduction is adequate for
long-term maintenance because the platelet count often
rebounds in ET patients [4]. In our case, plateletpheresis
might have been effective, but our hospital did not have
the necessary equipment.
Thrombocytosis (platelet count >40 × 104/μl) is known
to cause heparin resistance [11], as seen in several case
reports described above. Heparin resistance is usually
defined as the failure to achieve an ACT of 480 s after
450 IU/kg of heparin [12]. Heparin resistance can be
caused by mechanisms independent of AT or mecha-
nisms related to AT deficiency. The former mechanisms
are nonspecific and poorly defined. The risk factors are
abnormal platelets; intravenous administration of nitro-
glycerin; and increased heparin-binding proteins, such as
chemokines, extracellular matrix proteins, growth fac-
tors, enzymes, and miscellaneous proteins (factor VIII,
von Willebrand factor, and so on). After intravenous ad-
ministration, heparin can bind to several molecules and
platelets that can result in reduced biologic availability.
By this mechanism, thrombocytosis might cause heparin
resistance. However, the extent to which each of these
risk factors contributes to the phenomenon of heparin
resistance in the cardiac surgical population is not clear
[13]. Clinically significant heparin resistance is suspected
to be caused by either AT III deficiency or type 2
heparin-induced thrombocytopenia [14]. Although in
many cases heparin addition resolves heparin resistance,
sometimes administration of FFP or AT III is necessary
for AT III deficiency [12].
AT III is one of the main natural coagulation system
inhibitors. It inhibits not only thrombin and factor Xa
but also factors IXa, XIa, and XIIa, kallikrein, and plas-
min. Antithrombin’s activity is potentiated by heparin
and may be a key component of the heparin response.
AT III levels are known to decrease after recent or active
thrombosis, surgical procedures, disseminated intravas-
cular coagulation, or full-dose heparin administration.
Full-dose heparin can lower AT III levels by 30 % within
several days, but the levels recover after discontinuing
heparin [15].
In our case, AT III administration and approximately
three times as much heparin as expected were needed in
order to carry out ECC. Possible reasons for the decrease
in AT III under CPB were because it was consumed by ad-
ministration of too much heparin, the surgical proced-
ure itself, and the patient’s hypercoagulable state.
Addition of heparin, administration of AT III, and coat-
ing the CPB circuit with heparin or macromolecular
polymer prevented clot formation and enabled safe
ECC. This suggested that in this case, heparin resist-
ance was caused by mechanisms independent of AT
and mechanisms related to AT deficiency.
To neutralize the heparin effect, protamine was titrated
stepwise while measuring ACT, so the dose of protamine
administered in our case was low. We did not want ACT
to be completely normalized because of the risk of
thrombophilia.
The patient’s platelet count gradually increased after the
surgery due to rebound phenomena, but anticoagulant
therapy with aspirin and warfarin prevented thrombotic
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events, and hydroxycarbamide reduced the platelet count
to a normal range. Anagrelide would have been inappro-
priate because of its cardiac depression side effect, and
JAK2 inhibitors could not be prescribed under health in-
surance in Japan. Alpha-interferon was not chosen be-
cause it is not a standard treatment for ET.
Conclusions
Addition of heparin, administration of AT III, and coat-
ing the CPB circuit with heparin or macromolecular
polymer prevented clot formation and enabled safe ECC
in a patient with ET and a high platelet count.
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